dEjournals Home Page
Competitio
Online ready Current Most Read Archives Search
Register Login

Competitio

Vol. 17 No. 1-2 (2018)
Papers

The macroeconomic possibilities of biosimilars in developed countries

Published:
2018-12-14
DOI Linkhttps://doi.org/10.21845/comp/2018/1-2/1
Author
Peter Halmosi
View
PDF (Hungarian)
Keywords
biosimilars developed countries healthcare expenses
License

Copyright (c) 2018 Péter Halmosi

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How To Cite
Selected Style: APA
Halmosi, P. (2018). The macroeconomic possibilities of biosimilars in developed countries. Competitio, 17(1-2), 3-18. https://doi.org/10.21845/comp/2018/1-2/1
Abstract

Biosimilars have been used for the treatment of chronic diseases since 2006 in the EU but only since 2015 in the U.S. Despite high market potentials and presumed positive macroeconomic effects in the health care sector, widespread usage is strongly confronted with the opposition of physicians and pharmacists. However, biosimilars are supposed to reform health care financing, alter market positions of pharmaceutical companies and amend informational triangle among physicians, patients and insurance companies in the near future. The use of biosimilars is supposed by experts to reach extra health related savings even if doctors and pharmacists are averse to offer these products to patients in a certain therapeutic area. Governments have currently found no unique way of regulating the marketing, substitution and price regulation of biosimilars. The aim of this study is to discuss the macroeconomic possibilities and barriers incarnated in the usage of biosimilars in developed countries.

Journal of Economic Literature (JEL) codes: H51, I11, I12, J18

References
  1. Azevedo, V. – Dörner, T. – Strohal, R. – Isaacs, J. – Castaneda-Hernandez, G. – McInnes, I. (2017): Biosimilars: considerations for clinical practice Considerations in Medicine 2017; https://doi.org/10.1136/conmed-2017-100005. Letöltve: 2018. június 5.
  2. Baji, P. – Gulácsi, L. – Lovász, B. D. – Golovics, P. A. – Brodszky, V. – Péntek, M. – Rencz, F. – Lakatos, P. L. (2016): Treatment preferences of originator versus biosimilar drugs in Crohn’s disease; discrete choice experiment among gastroenterologists. Scand J Gastroenterol. 2016 Jan;51(1):22-7. Epub 2015 Jun 10. https://doi.org/10.3109/00365521.2015.1054422 Letöltve: 2018. május 4.
  3. Blackstone, E. A. – Joseph, P. Fuhr (2013): The economics of biosimilars. Am Health Drug Benefits 2013. Sept-Oct. 6(8) 469-478. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031732/ Letöltve: 2018. június 12.
  4. Bochenek, T. (szerk. 2017): Policies for biosimilar uptake in Europe: An overview. https://doi.org/10.1371/journal.pone.0190147 Letöltve: 2018. június 23.
  5. Chu, R. – Pugatch, M. (2009): Biogenerics or Biosimilars? Discussing the Present, Considering the Future. Stockholm Network.
  6. Cohen, JP – Felix, AE – Riggs, K (2014. et al.): Barriers to market uptake of biosimilars in the US: generics and biosimilars initiative. GaBI J. 2014;3(3):108-115. https://doi.org/10.5639/gabij.2014.0303.028
  7. Dankó, D. – Frang, G. A. – Girbicz, N. – Molnár, M. P. (2011): Alternatívák a biohasonló gyógyszerek fenntartható közfinanszírozási rendszerére. Budapesti Corvinus Egyetem Vezetéstudományi Intézet. pharmaonline.hu/download.php?id=6625 Letöltve: 2018. május 14.
  8. Deloitte (2015): Winning with biosimilars. Opportunities in global markets. https://www2.deloitte.com/content/dam/.../us-lshc-biosimilars-whitepaper-final.pdf Letöltve: 2018. június 26.
  9. European Medicine Agency (2017): Annual Report 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Annual_report/2018/04/WC500248201.pdf Letöltve: 2018. augusztus 17.
  10. Grabowsky, H. – Long, G. – Mortimer, R. (2011): Implementation of the biosimilar pathway: Economic and policy issues. Seton Hall Law Review. https://scholarship.shu.edu/cgi/viewcontent.cgi?article=1381&context=shlr Letöltve: 2018. június 27.
  11. Gulácsi, L. – Brodszky, V. – Baji, P. – HoUng, K. – Su Yeon, K. – Yu Young, C. – Péntek, M. (2015): Biosimilars for the management of rheumatoid arthritis: economics considerations. Expert Review of Clinical Immunology11: sup1, 43-52, https://doi.org/10.1586/1744666X.2015.1090313 Letöltve: 2018. július 15.
  12. Hornyák, L. – Nagy, Zs. – Tálos, Zs. – Endrei, D. – Ágoston, I. – Csákvári, T. – Boncz, I. (2014): A biohasonló gyógyszerek árversenyének tapasztalatai Magyarországon. Acta Pharmaceutica Hungarica. 2014/2, 83-87. o.
  13. IMS Institute for Healthcare Informatics (2016): Delivering on the potential of biosimilar medicines. The role of functioning competitive markets. https://www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf Letöltve: 2018. augusztus 8.
  14. Kerpel-Fronius, S. (2012a): Hasonlóságok és különbségek a kémiai és a biológiai követő gyógyszerek fejlesztésében, alkalmazásában. Orvostovábbképző Szemle
  15. XIX. évf. 7-8. szám, 2012. július-augusztus.
  16. Kerpel-Fronius, S. (2012b): Követő, biohasonló ellenanyagok fejlesztésének és alkalmazásának klinikai farmakológiai szempontjai. Magyar Onkológia 56: 104-112.o.
  17. Marketsandmarkets (2018): Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, rHGH, Interferon), Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing Type (In-house, Contract), Disease (Oncology, Autoimmune) - Global Forecast to 2023. https://www.marketsandmarkets.com/PressReleases/global-biosimilars-product-market-worth-19.4-billion-by-2014.asp). Letöltve: 2018. június 23.
  18. Mehr, S. R. – Richard A. Brook, R. A. (2017): Factors influencing the economics of biosimilars in the US, Journal of Medical Economics, 20:12, 1268-1271, https://doi.org/10.1080/13696998.2017.1366325 Letöltve: 2018. június 23.
  19. Nabhan, C. – Feinberg, B. A. (2017): Behavioral economics and the future of biosimilars. Journal of the National Comprehensive Cancer Network. 2017;15:1449-1451 https://doi.org/10.6004/jnccn.2017.7023
  20. Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet (2017): Biohasonló gyógyszerek az Európai Unió tagországaiban. Budapest
  21. Richter Gedeon Vegyészeti Gyár Nyrt. (2016): Biohasonló készítmények fejlesztési kihívásai. MEDinPROT konferencia, 2016. április 9. Budapest. medinprot.chem.elte.hu/.../I_3.Medinprot%20BE%2009.04.2016.p... Letöltve: 2018. június 23. Letöltve: 2018. június 2.
  22. Roediger, A. – Freischem, B. – Reiland, J.B. (2017): What pricing and reimbursement policies to use for off-patent biologicals in Europe? – results from the second EBE biological medicines policy survey. Generics and Biosimilars Initiative Journal (GaBI Journal). 2017;6(2):61-78. https://doi.org/10.5639/gabij.2017.0602.014 Letöltve: 2018. június 2.
  23. Singh, S. C. – Bagnato, K. M. (2015): The economic implications of biosimilars. Am J Manag Care. 2015;21:S331-S340
  24. Vogler, S. – Schneider, P. (2017): Do pricing and usage-enhancing policies differ between biosimilars and generics? Findings from an international survey. https://doi.org/10.5639/gabij.2017.0602.015 Letöltve: 2018. június 3.